TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007
June 27 2018 - 4:00PM
REGULATED
INFORMATION
PRESS RELEASE
Transparency
notification
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium)
- June 27, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and
Nasdaq: TIG; "TiGenix") announced today that it received a
transparency notification pursuant to Article 14 of the Belgian Law
of May 2, 2007 regarding the publication of major holdings in
issuers whose securities are admitted to trading on a regulated
market and including various provisions.
Summary of the
notification
On June 22, 2018, TiGenix received
a transparency notification from Sand Grove Capital Management LLP,
following the disposal of voting securities or voting rights on
June 6, 2018, after which Sand Grove Capital Management LLP
downward crossed the lowest threshold (3%) of total voting rights
of TiGenix.
Content of the
notification
Date of the
notification: June 21, 2018.
Reason of the
notification: acquisition or disposal of voting securities or
voting rights / downward crossing of the lowest threshold.
Person subject to
the notification requirement: Sand Grove Capital Management LLP
(with address at 4th floor, 35 Dover Street, London W1S 4NQ), who
is a person that notifies alone.
Date on which the
threshold was crossed: June 6, 2018.
Threshold that
was crossed: 3%.
Denominator:
296,067,856.
Details of the
notification: Following the disposal of voting securities or
voting rights, the number of voting rights was as follows: Sand
Grove Capital Management LLP held 0 voting securities (0% of the
total number of voting rights).
Chain of
controlled undertakings through which the holding is effectively
held: Sand Grove Capital Management LLP is not a controlled
entity.
Additional
information: Sand Grove Capital Management LLP acts as the
investment manager for the Sand Grove Opportunities Master Fund Ltd
and the Sand Grove Tactical Fund LP. Sand Grove Capital Management
LLP can exercise voting rights at its discretion without any
instruction from its clients.
This press release and the above-mentioned
transparency notification can be consulted on our website:
For more
information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV
(Euronext Brussels and NASDAQ: TIG) is an advanced
biopharmaceutical company developing novel therapies for serious
medical conditions by exploiting the anti-inflammatory properties
of allogeneic, or donor-derived, stem cells.
TiGenix lead
product, Alofisel (darvadstrocel), previously Cx601, received
European Commission (EC) approval for the treatment of complex
perianal fistulas in adult patients with non-active/mildly active
luminal Crohn's disease, when fistulas have shown an inadequate
response to at least one conventional or biologic therapy. A global
Phase III trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: TiGenix via Globenewswire
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024